{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:42:08Z","timestamp":1782924128826,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The tegument protein pp150 of Human Cytomegalovirus (HCMV) is known to be essential for the final stages of virus maturation and mediates its functions by interacting with capsid proteins. Our laboratory has previously identified the critical regions in pp150 important for pp150-capsid interactions and designed peptides similar in sequence to these regions, with a goal to competitively inhibit capsid maturation. Treatment with a specific peptide (PepCR2 or P10) targeted to pp150 conserved region 2 led to a significant reduction in murine CMV (MCMV) growth in cell culture, paving the way for in vivo testing in a mouse model of CMV infection. However, the general pharmacokinetic parameters of peptides, including rapid degradation and limited tissue and cell membrane permeability, pose a challenge to their successful use in vivo. Therefore, we designed a biopolymer-stabilized elastin-like polypeptide (ELP) fusion construct (ELP-P10) to enhance the bioavailability of P10. Antiviral efficacy and cytotoxic effects of ELP-P10 were studied in cell culture, and pharmacokinetics, biodistribution, and antiviral efficacy were studied in a mouse model of CMV infection. ELP-P10 maintained significant antiviral activity in cell culture, and this conjugation significantly enhanced P10 bioavailability in mouse tissues. The fluorescently labeled ELP-P10 accumulated to higher levels in mouse liver and kidneys as compared to the unconjugated P10. Moreover, viral titers from vital organs of MCMV-infected mice indicated a significant reduction of virus load upon ELP-P10 treatment. Therefore, ELP-P10 has the potential to be developed into an effective antiviral against CMV infection.<\/jats:p>","DOI":"10.1038\/s41598-024-60691-6","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T05:01:44Z","timestamp":1714798904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Elastin-like Polypeptide-fusion peptide targeting capsid-tegument interface as an antiviral against cytomegalovirus infection"],"prefix":"10.1038","volume":"14","author":[{"given":"Komal","family":"Beeton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipanwita","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adesanya A.","family":"Akinleye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Gene L.","family":"Bidwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"key":"60691_CR1","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1128\/jvi.65.12.6581-6588.1991","volume":"65","author":"CE Ibanez","year":"1991","unstructured":"Ibanez, C. E., Schrier, R., Ghazal, P., Wiley, C. & Nelson, J. A. Human cytomegalovirus productively infects primary differentiated macrophages. J. Virol. 65, 6581\u20136588 (1991).","journal-title":"J. Virol."},{"key":"60691_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.exphem.2005.11.012","volume":"34","author":"MG Bego","year":"2006","unstructured":"Bego, M. G. & Jeor, S. S. Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency. Exp. Hematol. 34, 555\u2013570 (2006).","journal-title":"Exp. Hematol."},{"key":"60691_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","volume":"19","author":"P Griffiths","year":"2021","unstructured":"Griffiths, P. & Reeves, M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat. Rev. Microbiol. 19, 759\u2013773 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"60691_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000454772","volume":"59","author":"K Zedtwitz-Liebenstein","year":"2016","unstructured":"Zedtwitz-Liebenstein, K., Diab-Elschahaw, M. & Frass, M. Human cytomegalovirus infection in nonimmunocompromised patients: A retrospective analysis and review of the literature. Intervirology 59, 159\u2013162 (2016).","journal-title":"Intervirology"},{"key":"60691_CR5","first-page":"113","volume":"66","author":"TW Cheung","year":"1999","unstructured":"Cheung, T. W. & Teich, S. A. Cytomegalovirus infection in patients with HIV infection. Mt. Sinai J. Med. N. Y. 66, 113\u2013124 (1999).","journal-title":"Mt. Sinai J. Med. N. Y."},{"key":"60691_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fcimb.2020.00280","volume":"10","author":"C-H Lee","year":"2020","unstructured":"Lee, C.-H. & Grey, F. Systems virology and human cytomegalovirus: Using high throughput approaches to identify novel host-virus interactions during lytic infection. Front. Cell. Infect. Microbiol. 10, 14 (2020).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"60691_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/pch\/4.1.35","volume":"4","author":"S Friedman","year":"1999","unstructured":"Friedman, S. & Ford-Jones, E. L. Congenital cytomegalovirus infection\u2014an update. Paediatr. Child Health 4, 35\u201338 (1999).","journal-title":"Paediatr. Child Health"},{"key":"60691_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/1753495X14552719","volume":"7","author":"WJ van Zuylen","year":"2014","unstructured":"van Zuylen, W. J. et al. Congenital cytomegalovirus infection: Clinical presentation, epidemiology, diagnosis and prevention. Obstet. Med. 7, 140\u2013146 (2014).","journal-title":"Obstet. Med."},{"key":"60691_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","volume":"71","author":"KK Biron","year":"2006","unstructured":"Biron, K. K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71, 154\u2013163 (2006).","journal-title":"Antiviral Res."},{"key":"60691_CR10","doi-asserted-by":"publisher","first-page":"10960","DOI":"10.1128\/JVI.78.20.10960-10966.2004","volume":"78","author":"SM Varnum","year":"2004","unstructured":"Varnum, S. M. et al. Identification of proteins in human cytomegalovirus (HCMV) particles: The HCMV proteome. J. Virol. 78, 10960\u201310966 (2004).","journal-title":"J. Virol."},{"key":"60691_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1128\/MMBR.00040-07","volume":"72","author":"RF Kalejta","year":"2008","unstructured":"Kalejta, R. F. Tegument proteins of human cytomegalovirus. Microbiol. Mol. Biol. Rev. 72, 249\u2013265 (2008).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"60691_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/sj.icb.7100013","volume":"85","author":"AA Scalzo","year":"2007","unstructured":"Scalzo, A. A., Corbett, A. J., Rawlinson, W. D., Scott, G. M. & Degli-Esposti, M. A. The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol. Cell Biol. 85, 46\u201354 (2007).","journal-title":"Immunol. Cell Biol."},{"key":"60691_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/ni1190","volume":"6","author":"TI Arnon","year":"2005","unstructured":"Arnon, T. I. et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat. Immunol. 6, 515\u2013523 (2005).","journal-title":"Nat. Immunol."},{"key":"60691_CR14","doi-asserted-by":"crossref","unstructured":"Hellberg, T., Pa\u00dfvogel, L., Schulz, K. S., Klupp, B. G. & Mettenleiter, T. C. Chapter three\u2014nuclear egress of herpesviruses: The prototypic vesicular nucleocytoplasmic transport. In Advances in Virus Research, vol. 94 (eds. Kielian, M. et al.) 94 81\u2013140 (Academic Press, 2016).","DOI":"10.1016\/bs.aivir.2015.10.002"},{"key":"60691_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.tim.2012.04.008","volume":"20","author":"R Tandon","year":"2012","unstructured":"Tandon, R. & Mocarski, E. S. Viral and host control of cytomegalovirus maturation. Trends Microbiol. 20, 392 (2012).","journal-title":"Trends Microbiol."},{"key":"60691_CR16","doi-asserted-by":"publisher","first-page":"e1002878","DOI":"10.1371\/journal.ppat.1002878","volume":"8","author":"JC Alwine","year":"2012","unstructured":"Alwine, J. C. The human cytomegalovirus assembly compartment: A masterpiece of viral manipulation of cellular processes that facilitates assembly and egress. PLoS Pathog. 8, e1002878 (2012).","journal-title":"PLoS Pathog."},{"key":"60691_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.devcel.2018.03.010","volume":"45","author":"DJ Procter","year":"2018","unstructured":"Procter, D. J. et al. The HCMV Assembly Compartment is a dynamic Golgi-derived MTOC that controls nuclear rotation and virus spread. Dev. Cell 45, 83-100.e7 (2018).","journal-title":"Dev. Cell"},{"key":"60691_CR18","doi-asserted-by":"publisher","first-page":"8199","DOI":"10.1128\/JVI.00457-06","volume":"80","author":"DP AuCoin","year":"2006","unstructured":"AuCoin, D. P., Smith, G. B., Meiering, C. D. & Mocarski, E. S. Betaherpesvirus-conserved cytomegalovirus tegument protein ppUL32 (pp150) controls cytoplasmic events during virion maturation. J. Virol. 80, 8199\u20138210 (2006).","journal-title":"J. Virol."},{"key":"60691_CR19","doi-asserted-by":"publisher","first-page":"9433","DOI":"10.1128\/JVI.00533-08","volume":"82","author":"R Tandon","year":"2008","unstructured":"Tandon, R. & Mocarski, E. S. Control of cytoplasmic maturation events by cytomegalovirus tegument protein pp150. J. Virol. 82, 9433\u20139444 (2008).","journal-title":"J. Virol."},{"key":"60691_CR20","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1128\/JVI.75.15.6865-6873.2001","volume":"75","author":"MK Baxter","year":"2001","unstructured":"Baxter, M. K. & Gibson, W. Cytomegalovirus basic phosphoprotein (pUL32) binds to capsids in vitro through its amino one-third. J. Virol. 75, 6865\u20136873 (2001).","journal-title":"J. Virol."},{"key":"60691_CR21","doi-asserted-by":"publisher","first-page":"e1003525","DOI":"10.1371\/journal.ppat.1003525","volume":"9","author":"X Dai","year":"2013","unstructured":"Dai, X. et al. The smallest capsid protein mediates binding of the essential tegument protein pp150 to stabilize DNA-containing capsids in human cytomegalovirus. PLoS Pathog. 9, e1003525 (2013).","journal-title":"PLoS Pathog."},{"key":"60691_CR22","doi-asserted-by":"publisher","first-page":"eaam6892","DOI":"10.1126\/science.aam6892","volume":"356","author":"X Yu","year":"2017","unstructured":"Yu, X., Jih, J., Jiang, J. & Zhou, Z. H. Atomic structure of the human cytomegalovirus capsid with its securing tegument layer of pp150. Science 356, eaam6892 (2017).","journal-title":"Science"},{"key":"60691_CR23","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3390\/v13112277","volume":"13","author":"D Mitra","year":"2021","unstructured":"Mitra, D., Hasan, M. H., Bates, J. T., Bidwell, G. L. & Tandon, R. Tegument protein pp150 sequence-specific peptide blocks cytomegalovirus infection. Viruses 13, 2277 (2021).","journal-title":"Viruses"},{"key":"60691_CR24","doi-asserted-by":"publisher","first-page":"e0058618","DOI":"10.1128\/mSphere.00586-18","volume":"4","author":"JW Jackson","year":"2019","unstructured":"Jackson, J. W. et al. Anticytomegalovirus peptides point to new insights for CMV entry mechanisms and the limitations of in vitro screenings. mSphere 4, e0058618 (2019).","journal-title":"mSphere"},{"key":"60691_CR25","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.addr.2010.05.003","volume":"62","author":"GL Bidwell","year":"2010","unstructured":"Bidwell, G. L. & Raucher, D. Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. Adv. Drug Deliv. Rev. 62, 1486\u20131496 (2010).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"60691_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/pro.2063","volume":"21","author":"M Shah","year":"2012","unstructured":"Shah, M. et al. Biodegradation of elastin-like polypeptide nanoparticles. Protein Sci. Publ. Protein Soc. 21, 743\u2013750 (2012).","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"60691_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jconrel.2015.11.010","volume":"240","author":"J Despanie","year":"2016","unstructured":"Despanie, J., Dhandhukia, J. P., Hamm-Alvarez, S. F. & MacKay, J. A. Elastin-like polypeptides: Therapeutic applications for an emerging class of nanomedicines. J. Control. Release Off. J. Control. Release Soc. 240, 93\u2013108 (2016).","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"60691_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1152\/physiol.00026.2021","volume":"36","author":"GL Bidwell","year":"2021","unstructured":"Bidwell, G. L. Novel protein therapeutics created using the elastin-like polypeptide platform. Physiology 36, 367\u2013381 (2021).","journal-title":"Physiology"},{"key":"60691_CR29","doi-asserted-by":"publisher","first-page":"F139","DOI":"10.1152\/ajprenal.00155.2020","volume":"319","author":"AR Chade","year":"2020","unstructured":"Chade, A. R., Williams, M. L., Engel, J. E., Williams, E. & Bidwell, G. L. Molecular targeting of renal inflammation using drug delivery technology to inhibit NF-\u03baB improves renal recovery in chronic kidney disease. Am. J. Physiol. Renal Physiol. 319, F139\u2013F148 (2020).","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"75","key":"60691_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1161\/HYPERTENSIONAHA.119.13368","volume":"1979","author":"AC Eddy","year":"2020","unstructured":"Eddy, A. C. et al. Biopolymer-delivered, maternally sequestered NF-\u03baB (Nuclear Factor-\u03baB) inhibitory peptide for treatment of preeclampsia. Hypertens. Dallas Tex 1979(75), 193\u2013201 (2020).","journal-title":"Hypertens. Dallas Tex"},{"key":"60691_CR31","doi-asserted-by":"publisher","first-page":"e55104","DOI":"10.1371\/journal.pone.0055104","volume":"8","author":"GL Bidwell","year":"2013","unstructured":"Bidwell, G. L. et al. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PloS One 8, e55104 (2013).","journal-title":"PloS One"},{"key":"60691_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.canlet.2011.12.042","volume":"319","author":"GL Bidwell","year":"2012","unstructured":"Bidwell, G. L., Perkins, E. & Raucher, D. A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett. 319, 136\u2013143 (2012).","journal-title":"Cancer Lett."},{"key":"60691_CR33","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.peptides.2010.02.007","volume":"31","author":"GL Bidwell","year":"2010","unstructured":"Bidwell, G. L. et al. A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation. Peptides 31, 834\u2013841 (2010).","journal-title":"Peptides"},{"key":"60691_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ijc.24725","volume":"126","author":"I Massodi","year":"2010","unstructured":"Massodi, I., Moktan, S., Rawat, A., Bidwell, G. L. & Raucher, D. Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. Int. J. Cancer 126, 533\u2013544 (2010).","journal-title":"Int. J. Cancer"},{"key":"60691_CR35","doi-asserted-by":"publisher","first-page":"e23077","DOI":"10.1096\/fj.202300309RR","volume":"37","author":"JA Howell","year":"2023","unstructured":"Howell, J. A. et al. Elastin-like polypeptide delivery of anti-inflammatory peptides to the brain following ischemic stroke. FASEB J. 37, e23077 (2023).","journal-title":"FASEB J."},{"key":"60691_CR36","doi-asserted-by":"publisher","unstructured":"Hinderliter, P. & Saghir, S. A. Pharmacokinetics. In Encyclopedia of Toxicology (Third Edition) (ed. Wexler, P.) 849\u2013855 (Academic Press, 2014). https:\/\/doi.org\/10.1016\/B978-0-12-386454-3.00419-X.","DOI":"10.1016\/B978-0-12-386454-3.00419-X"},{"key":"60691_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5500\/wjt.v10.i7.183","volume":"10","author":"BC Lizaola-Mayo","year":"2020","unstructured":"Lizaola-Mayo, B. C. & Rodriguez, E. A. Cytomegalovirus infection after liver transplantation. World J. Transplant. 10, 183\u2013190 (2020).","journal-title":"World J. Transplant."},{"key":"60691_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/infdis\/148.3.406","volume":"148","author":"DA Katzenstein","year":"1983","unstructured":"Katzenstein, D. A., Yu, G. S. M. & Jordan, M. C. Lethal infection with murine cytomegalovirus after early viral replication in the spleen. J. Infect. Dis. 148, 406\u2013411 (1983).","journal-title":"J. Infect. Dis."},{"key":"60691_CR39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/infdis\/167.2.264","volume":"167","author":"JD Shanley","year":"1993","unstructured":"Shanley, J. D., Biczak, L. & Forman, S. J. Acute murine cytomegalovirus infection induces lethal hepatitis. J. Infect. Dis. 167, 264\u2013269 (1993).","journal-title":"J. Infect. Dis."},{"key":"60691_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1099\/vir.0.006668-0","volume":"90","author":"KM Hsu","year":"2009","unstructured":"Hsu, K. M., Pratt, J. R., Akers, W. J., Achilefu, S. I. & Yokoyama, W. M. Murine cytomegalovirus displays selective infection of cells within hours after systemic administration. J. Gen. Virol. 90, 33\u201343 (2009).","journal-title":"J. Gen. Virol."},{"key":"60691_CR41","doi-asserted-by":"publisher","first-page":"e1002366","DOI":"10.1371\/journal.ppat.1002366","volume":"7","author":"T Sacher","year":"2011","unstructured":"Sacher, T. et al. Shedding light on the elusive role of endothelial cells in cytomegalovirus dissemination. PLOS Pathog. 7, e1002366 (2011).","journal-title":"PLOS Pathog."},{"key":"60691_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.chom.2008.02.014","volume":"3","author":"T Sacher","year":"2008","unstructured":"Sacher, T. et al. The major virus-producing cell type during murine cytomegalovirus infection, the hepatocyte, is not the source of virus dissemination in the host. Cell Host Microbe 3, 263\u2013272 (2008).","journal-title":"Cell Host Microbe"},{"key":"60691_CR43","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","volume":"9","author":"C Wild","year":"1993","unstructured":"Wild, C., Greenwell, T. & Matthews, T. A synthetic peptide from HIV-1 gp41 Is a potent inhibitor of virus-mediated cell\u2014cell fusion. AIDS Res. Hum. Retroviruses 9, 1051\u20131053 (1993).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"60691_CR44","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1128\/JVI.01902-09","volume":"84","author":"A Schulze","year":"2010","unstructured":"Schulze, A., Schieck, A., Ni, Y., Mier, W. & Urban, S. Fine mapping of Pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J. Virol. 84, 1989\u20132000 (2010).","journal-title":"J. Virol."},{"key":"60691_CR45","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1158\/1535-7163.MCT-04-0253","volume":"4","author":"GL Bidwell","year":"2005","unstructured":"Bidwell, G. L. & Raucher, D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol. Cancer Ther. 4, 1076\u20131085 (2005).","journal-title":"Mol. Cancer Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60691-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60691-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60691-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T05:02:06Z","timestamp":1714798926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60691-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["60691"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-60691-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,4]]},"assertion":[{"value":"31 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.L.B. is the owner of Leflore Technologies and is inventor on patents related to ELP drug delivery technology. Leflore Technologies had no input on the design, conduct, data interpretation, or publication of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10253"}}